Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Eyeball

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Eyeball. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2021-004015-11 Sponsor Protocol Number: MAD2021-07 Start Date*: 2022-11-11
    Sponsor Name:Erasmus MC
    Full Title: Investigator led, double-masked, multicenter, randomized clinical trial for the comparison of Atropine 0.5% versus Atropine 0.05% eye drops for the prevention of myopia progression in Dutch children.
    Medical condition: Myopia
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002825-31 Sponsor Protocol Number: INTV-STC-RT-SI-2012 Start Date*: 2012-07-01
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: NEW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: INTRAVITREAL AND SUBCONJUNCITIVAL INJECTION OF CHEMOTHERAPY in the intraoculars RTBs
    Medical condition: patients with RTB
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10030054 Ocular neoplasms HLGT
    14.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004981-16 Sponsor Protocol Number: 1991-201-008 Start Date*: 2022-06-17
    Sponsor Name:Editas Medicine, Inc.
    Full Title: Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Efficacy of EDIT-101 in Adult and Pediatric Participants with Leber Congenital Amaurosis Type 10 (LCA10), with Cen...
    Medical condition: Leber Congenital Amaurosis Type 10 (LCA10), with Centrosomal Protein 290 (CEP290)-Related Retinal Degeneration Caused by a Compound Heterozygous or Homozygous Mutation Involving c.2991+1655A>G in I...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10015920 Eye disorders congenital HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-003910-33 Sponsor Protocol Number: -- Start Date*: 2007-11-19
    Sponsor Name:OSPEDALE MAGGIORE DI MILANO (IRCCS)
    Full Title: Randomized controlled study of rituximab and steroid treatment in thyroid-associeted ophthalmopathy (TAO)
    Medical condition: Thyroid associeted ophthalmopathy.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10015919 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005583-14 Sponsor Protocol Number: ART-OFT-RTB-SI-2008 Start Date*: 2008-09-15
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: NEW CONSERVATIVE THERAPIES IN RETINOBLASTOMA: DIRECT INTRAARTERIAL (OPHTALMIC ARTERY) CHEMOTHERAPY WITH MELPHALAN FOR INTRAOCULAR RETINOBLASTOMA
    Medical condition: patients with retinoblastoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015919 Eye disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-000540-15 Sponsor Protocol Number: SPON1266-14 Start Date*: 2014-05-01
    Sponsor Name:Cardiff University
    Full Title: Prostaglandin F2-alpha eye drops (Bimatoprost) in thyroid eye disease: a randomised controlled double blind crossover trial
    Medical condition: Graves' ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000780-42 Sponsor Protocol Number: Latanoprost 1/2007 Start Date*: 2008-02-20
    Sponsor Name:PH&T SPA
    Full Title: Evaluation of the therapeutic equivalence of latanoprost PK and Xalatan. Double blind randomized clinical trial in subjects affected by open angle glaucoma or intraocular hypertension.
    Medical condition: Subjects affected by glaucoma or intraocular hypertension.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015919 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004320-36 Sponsor Protocol Number: DMS/AVASTIN 2006 Start Date*: 2006-07-25
    Sponsor Name:AZIENDA OSPEDALIERA SENESE
    Full Title: Intravitreal Bevacizumab (Avastin) for neovascular age-related macular degeneration
    Medical condition: Viasual acuity loss
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001468-34 Sponsor Protocol Number: HLS01/2008 Start Date*: 2008-11-20
    Sponsor Name:AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
    Full Title: Phase III clinical trial multicenter randomized for the evaluation of the safety and efficacy of the combined treatment of intravitreal triamcinolone and photodynamic therapy versus intravitreal Be...
    Medical condition: Choroideal neo-vascularization type RAP.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015919 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001502-17 Sponsor Protocol Number: FARM6FYZB3 Start Date*: 2007-11-15
    Sponsor Name:AZIENDA OSPEDALIERA MEYER
    Full Title: MULTICENTRIC COMPARATIVE RANDOMIZED DOUBLE BLIND CROSS OVER STUDY WITH TACROLIMUS (FK506)0.1% EYEDROPS AND CYCLOSPORINE 1% EYEDROPS IN CHILDREN WITH SEVERE ACTIVE VERNAL KERATOCONJUNCTIVITIS, LASTI...
    Medical condition: Vernal Keratoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015919 Eye disorders SOC
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001971-36 Sponsor Protocol Number: RETAANE PED Start Date*: 2005-05-25
    Sponsor Name:OSPEDALE S. RAFFAELE
    Full Title: PILOT, OPEN NON COMPARATIVE CLINICAL STUDY TO EVALUATE THE EFFICAY AND SAFETY OF RETAANE (ANECORTAVE ACETATO 15 MG, 0.5 ML DI 30 MG/ML ANECORTAVE ACETATO STERILE SUSPENSION) IN PATIENTS WITH COROID...
    Medical condition: RETAANE TREATMENT OF COROIDEAL NEOVASCULARIZATION FORMS SECONDARY TO SENILE MACULAR DEGENERATION
    Disease: Version SOC Term Classification Code Term Level
    6.1 10015919 SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000425-72 Sponsor Protocol Number: RET-01-11 Start Date*: 2011-01-25
    Sponsor Name:IRCCS- FONDAZIONE G.B. BIETTI PER LO STUDIO E LA RICERCA IN OFTALMOLOGIA-ONLUS
    Full Title: Treatment of macular edema secondary to central or branch vein occlusion by dexamethazone intravitreal injection
    Medical condition: macular edema seconday to central or branch retinal vein occlusion
    Disease: Version SOC Term Classification Code Term Level
    13.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005419-10 Sponsor Protocol Number: TRAVOPROSTPR1/2011 Start Date*: 2012-02-29
    Sponsor Name:PH&T SPA
    Full Title: EVALUATION OF THE THERAPEUTIC EQUIVALENCE OF TRAVOPROST PR AND TRAVATAN. DOUBLE BLIND RANDOMIZED CLINICAL TRIAL IN SUBJECTS AFFECTED BY GLAUCOMA OR INTRAOCULAR HYPERTENSION.
    Medical condition: Primary open angle glaucoma (POAG) or ocular hypertension (OH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002172-27 Sponsor Protocol Number: NGF0116 Start Date*: 2016-11-09
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: A 8 weeks, Phase II, single-centre, randomized, double-masked, vehicle-controlled, parallel group study with 4 weeks of follow-up to evaluate preliminary efficacy and safety of recombinant human Ne...
    Medical condition: patients after cataract and refractive surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005621-30 Sponsor Protocol Number: 541 Start Date*: 2008-07-03
    Sponsor Name:BAUSCH&LOMB
    Full Title: A multicenter, Investigator - masked, parallel-group, randomized study of the efficacy and safety of loteprednol etabonate 0.5% eyedrops versus dexamethasone 0.1% eyedrops in the treatment of ocula...
    Medical condition: Subjects scheduled to undergo cataract surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-007872-40 Sponsor Protocol Number: ROPP-2008-01 Start Date*: 2014-08-19
    Sponsor Name:Premacure AB, A member of the Shire Group of Companies
    Full Title: Determination of the rhIGF-I/rhIGFBP-3 Dose; Administered as a Continuous Infusion, Required to Establish and Maintain Longitudinal Serum IGF-I Levels within Physiological Levels in Premature Infan...
    Medical condition: Retinopathy of Prematurity (ROP)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) GB (Completed) IT (Completed) NL (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005119-17 Sponsor Protocol Number: BAY86-5321/17850 Start Date*: 2015-05-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept acco...
    Medical condition: Diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    18.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) IT (Completed) LT (Completed) ES (Completed) PT (Completed) FR (Completed) DE (Completed) AT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004938-25 Sponsor Protocol Number: BAY86-5321/17613 Start Date*: 2016-07-07
    Sponsor Name:Bayer AG
    Full Title: An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of three different treatment regimens of 2 mg aflibercept administered by intr...
    Medical condition: Diabetic macular edema (DME)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10015919 - Eye disorders 10057934 Diabetic macular edema LLT
    19.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SK (Completed) HU (Completed) DE (Completed) AT (Completed) ES (Completed) CZ (Completed) LT (Completed) FR (Completed) PT (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004736-24 Sponsor Protocol Number: OPT-302-1004 Start Date*: 2021-07-19
    Sponsor Name:Opthea Limited
    Full Title: A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Ranibizumab, Compared with Ranibizumab Alone, in Participants...
    Medical condition: Neovascular age-related macular degeneration (wet AMD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10015919 Eye disorders SOC
    20.0 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    20.1 10015919 - Eye disorders 10067791 Wet macular degeneration LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) DK (Trial now transitioned) BG (Completed) PL (Trial now transitioned) ES (Ongoing) LV (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000120-33 Sponsor Protocol Number: BAY86-5321/16598 Start Date*: 2015-08-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two differen...
    Medical condition: Neovascular Age-Related Macular Degeneration (nAMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) PT (Completed) LT (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 21:15:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA